Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.7400
-0.0142 (-1.88%)
At close: Feb 27, 2026, 4:00 PM EST
0.7546
+0.0146 (1.97%)
After-hours: Feb 27, 2026, 7:48 PM EST

Citius Pharmaceuticals Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Selling, General & Admin
31.4629.3730.0921.9115.6611.29
Research & Development
8.639.1611.9114.8217.6612.24
Operating Expenses
40.0938.534236.7333.3223.53
Operating Income
-36.93-38.53-42-36.73-33.32-23.53
Interest Expense
-0.42-0.27----0.01
Interest & Investment Income
0.130.110.761.180.250.26
EBT Excluding Unusual Items
-37.22-38.68-41.24-35.55-33.06-23.28
Gain (Loss) on Sale of Assets
--2.393.59--
Other Unusual Items
-----0.23
Pretax Income
-37.8-38.68-38.85-31.97-33.06-23.05
Income Tax Expense
1.061.060.580.580.58-
Earnings From Continuing Operations
-38.85-39.74-39.43-32.54-33.64-23.05
Minority Interest in Earnings
2.972.310.29---
Net Income
-35.89-37.43-39.14-32.54-33.64-23.05
Preferred Dividends & Other Adjustments
--1.051.15-1.45
Net Income to Common
-35.89-37.43-40.19-33.69-33.64-24.51
Shares Outstanding (Basic)
15117664
Shares Outstanding (Diluted)
15117664
Shares Change (YoY)
107.77%64.49%11.16%3.57%34.52%177.28%
EPS (Basic)
-2.46-3.38-5.97-5.57-5.76-5.64
EPS (Diluted)
-2.46-3.38-5.97-5.57-5.76-5.64
Free Cash Flow
-34.84-26.55-28.2-29.06-28.36-24.26
Free Cash Flow Per Share
-2.39-2.40-4.19-4.80-4.85-5.58
EBITDA
-36.36-38.52-41.99-36.73-33.31-23.53
D&A For EBITDA
0.5700000
EBIT
-36.93-38.53-42-36.73-33.32-23.53
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q